查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1198490

支架市场 - 增长、趋势、COVID-19 影响和预测 (2023-2028)

Stents Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 112 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

在预测期内，支架市场预计将以 5.3% 的复合年增长率增长。

COVID-19 的早期影响受到了世界各地取消择期手术（包括外科手术）的负面影响。 例如，世卫组织于 2020 年 5 月在 155 个国家进行的为期三週的调查发现，包括各种心血管疾病在内的各种慢性病的预防和治疗服务受到严重阻碍，慢性病患者经历了 COVID-19。有人指出，19相关的病情加重和死亡的风险很高。 一项重要发现是，超过一半 (53%) 的受调查国家部分或完全暂停了高血压护理服务，31% 的国家暂停了心血管急救服务，这影响了市场增长。 然而，随着全球外科手术的恢復，它开始在市场上受到关注。 根据欧盟统计局的数据，2020 年德国进行了近 38,900 例心臟搭桥手术。 预计在预测期内，心臟手术和支架植入术的数量将增加，这将对市场增长产生积极影响。

预计心臟相关疾病的高负担会增加血管成形术的数量，从而在预测期内促进市场增长。 此外，慢性病的增加、老年人口的增加以及支架开发的技术进步都对市场增长产生了积极影响。

根据《世界人口展望》，2022 年 65 岁及以上人口的比例估计为 9.7，到 2030 年将达到 11.7。 心房颤动是老年人主要的心律失常，可通过冠状动脉支架置入术治疗。 预计老年人口的快速增长将在预测期内推动市场增长。

此外，据 WSO 称，每年诊断出大约 500 万新的心房颤动和扑动病例。 所有年龄和性别的房颤发病率为 470 万，预计到 2022 年患病率将达到 6000 万。 预计在预测期内，房颤的高负担将扩大支架市场。

在过去十年中，慢性病的患病率有所增加。 据 AHA 称，到 2021 年，外周动脉疾病 (PAD) 将影响全球 2 亿多人，并且与高死亡率和发病率有关。 随着世界人口老龄化，PAD 在预测期内可能会变得越来越普遍。 统计数据显示，PAD 患者的数量正在以更快的速度增长，这最终推动了支架市场。

此外，根据 AHA 发表的科学研究，到 2021 年，全球将有超过 2.3 亿人受到外周下肢动脉疾病 (PAD) 的影响，并带来一些不利的临床后果（冠心病、中风等心血管疾病和肢体结果，如截肢情况）。 由于 PAD 的治疗需要支架，预计 PAD 发病率的增加最终将在预测期内推动支架市场。

此外，技术进步以及主要参与者的产品批准、合作伙伴关係和收购的增加正在推动市场的增长。 例如，2022 年 3 月，全球心血管技术公司 Cordis 的 Smart Radianz 血管支架系统获得 FDA 批准，这是一种专门为外周桡动脉手术设计的自扩张支架。 预计此类技术进步将在全球范围内增加支架在有效根治性治疗中的应用。

因此，由于上述因素，该市场有望在预测期内增长。 然而，严格的支架审批流程和频繁的产品召回可能会阻碍市场增长。

支架市场趋势

药物洗脱支架部分预计在预测期内增长

药物洗脱支架是置入堵塞和病变的外周动脉和冠状动脉内，缓慢释放药物抑制细胞增殖的支架，用于外周动脉和冠状动脉。

由于心脏病的增加，全球对冠状动脉支架的需求不断增加。 根据疾病预防控制中心的数据，到 2020 年，美国将有大约 2010 万 20 岁及以上的成年人患有冠心病 (CAD)。 它还指出，冠心病是美国最常见的心脏病类型。 人群中心脏病的高患病率已经收穫了对支架的需求。

技术进步、产品批准的增加以及主要参与者的合作伙伴关係和收购正在推动这一细分市场的增长。 例如，2022 年 1 月，Cook Medical 因其用于膝盖以下的新型药物洗脱支架 (BTK) 获得了美国 FDA 的突破性设备指定。 这种新型支架用于治疗威胁四肢的持续性缺血患者。 2021年8月，赛诺美在爱尔兰推出药物洗脱支架HT Supreme。 预计此类发布将在预测期内促进该细分市场的增长。

北美有望在预测期内主导支架市场

北美的特点是慢性病发病率上升、人口老龄化、行业参与者在该地区的强大影响力、出色的医疗保健基础设施以及人与行业之间在该地区可用技术方面的关係。预计消费者意识提高等因素垄断市场。

此外，人口老龄化的加剧和与生活方式相关的疾病发病率的上升对所调查市场的增长产生了积极影响。 例如，加拿大统计局的 2021 年人口普查显示，到 2021 年，65 岁及以上的人口将约为 7,021,430 人，其中男性 3,224,680 人，女性 3,796,750 人。 老年人口易患严重的心血管疾病，需要支架治疗。 因此，该地区老龄化人口的快速增加可能会增加市场增长。

由于用于不同条件的支架的创新，预计主要市场参与者和机构参与该地区的研发工作将促进市场增长。 例如，2021 年 10 月，波士顿科学公司将在拉斯维加斯举行的血管介入进展 (VIVA) 会议上的临床试验演示中展示 Eluvia 药物洗脱血管支架系统的积极临床试验结果。底部。 来自 EMINENT 试验的数据表明，Elvia 支架在治疗外周动脉疾病（PAD）和股浅动脉（SFA）病变长达 210 毫米的患者方面优于自扩张裸金属支架（BMS）。增加。 该研究招募了 775 名患者，使其成为迄今为止最大的药物洗脱支架治疗外周动脉疾病的随机试验。 此类临床试验有望促进支架在该地区的使用。

因此，由于上述因素，北美市场有望扩大。

支架市场竞争对手分析

由于公司在全球和区域开展业务，因此支架市场在本质上是分散的。 竞争格局包括对少数具有市场份额的知名国际和本地公司的分析。 一些主要的市场参与者是波士顿科学公司、雅培、美敦力、B. Brown、Becton、Dickinson and Company、Microport Scientific Inc.、Biotronik、Cook Group、Allium Medical Solutions Inc.、Elixir Medical、Terumo Corporation 等。

其他福利。

  • Excel 格式的市场预测 (ME) 表
  • 3 个月的分析师支持

内容

第1章介绍

  • 研究假设和市场定义
  • 调查范围

第2章研究方法论

第 3 章执行摘要

第4章市场动态

  • 市场概览
  • 市场驱动因素
    • 慢性病患病率增加
    • 老年人口增加
    • 支架开发的技术进步
  • 市场製约因素
    • 支架的严格审批流程
    • 产品回收率高
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模：百万美元）

  • 按产品分类
    • 冠状动脉支架
      • 药物洗脱支架
      • 裸金属冠状动脉支架
      • 生物可吸收支架
    • 外围设备支架
      • 髂支架
      • 股骨/腘窝支架
      • 肾臟和相关支架
      • 颈动脉支架
    • 支架植入物
  • 按材料
    • 金属生物材料
    • 高分子生物材料
    • 天然生物材料
  • 按地区细分
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲地区
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章竞争格局

  • 公司简介
    • Boston Scientific Corporation
    • Abbott
    • Medtronic
    • B. Braun SE
    • Becton, Dickinson and Company
    • Microport Scientific Corporation
    • Biotronik
    • Cook Group
    • Allium Medical Solutions Ltd
    • Elixir Medical
    • Terumo Corporation

第7章 市场机会与今后动向

简介目录
Product Code: 67149

The stents market is expected to register a CAGR of 5.3% during the forecast period.

The impact of COVID-19 in its initial phase was adverse due to the cancellations of elective procedures, including surgeries worldwide. For instance, a WHO survey conducted for 155 countries for three weeks in May 2020 indicated that the prevention and treatment services of various chronic diseases, including various cardiovascular disorders, had been severely disrupted, and people with chronic conditions were at a higher risk of severe COVID-19-related illness and death. The key finding suggested that more than half (53%) of the countries surveyed had partially or wholly disrupted services for hypertension treatment and 31% for cardiovascular emergencies, which impacted the growth of the market. However, the market started to gain traction owing to the resumption of surgical procedures worldwide. According to Eurostat, nearly 38,900 heart bypasses were conducted in Germany in 2020. The number of cardiac surgical procedures and stent implantations is projected to grow during the forecast period, positively impacting the growth of the market.

The high burden of heart-related diseases is expected to increase the number of angioplasties, thereby augmenting market growth during the forecast period. In addition, the increasing prevalence of chronic diseases, the growing geriatric population, and technological advancements in stent development are actively affecting the growth of the market.

According to the World Population Prospects, the percentage of the population aged 65 and over was 9.7 in 2022, and it is estimated to reach 11.7 in 2030. Atrial fibrillation is a major heart rhythm disorder among older people, which leads to coronary stent implantation for treatment. The surge in the geriatric population is projected to propel the growth of the market during the forecast period.

Additionally, as per the WSO, almost 5 million new cases of atrial fibrillation and flutter are diagnosed each year. The incidence of atrial fibrillation in all ages and sexes was 4.7 million, and the prevalence was expected to reach 60 million in 2022. The high burden of atrial fibrillation is projected to augment the stents market during the forecast period.

The prevalence of chronic illnesses has increased over the decade. According to the AHA, peripheral artery disease (PAD) affected more than 200 million people worldwide and was associated with high mortality and morbidity in 2021. With the aging global population, PAD may likely become increasingly common during the forecast period. Statistics show that the number of PAD patients is increasing at a faster pace, which is ultimately driving the market for stents.

Additionally, as per a scientific study published by the AHA, lower extremity peripheral artery disease (PAD) affected more than 230 million individuals worldwide in 2021, and it is linked to an elevated risk of several unfavorable clinical outcomes (including cardiovascular diseases like coronary heart disease and stroke and limb outcomes like amputee status). Since the treatment of PAD requires stents, the increased incidence of PAD is ultimately projected to boost the stents market during the forecast period.

Furthermore, the advancements in technology and the increasing number of product approvals, partnerships, and acquisitions by key players are helping the market grow. For instance, in March 2022, Cordis, a global cardiovascular technology company, received FDA approval for its Smart Radianz Vascular Stent System, a self-expanding stent designed explicitly for radial peripheral procedures. Such technological advancements are projected to boost the utility of stents worldwide for effective underlying treatments.

Therefore, owing to the abovementioned factors, it is anticipated that the market studied will witness growth over the forecast period. However, a stringent approval process for stents and high product recalls are likely to impede the growth of the market.

Stents Market Trends

The Drug-eluting Stents Segment is Expected to Witness Growth During the Forecast period

A drug-eluting stent is a peripheral or coronary stent inserted into clogged, diseased peripheral or coronary arteries, slowly releasing a drug to block cell proliferation.

Due to the increase in the number of cardiac disorders, there is an increased demand for coronary stents worldwide. According to the CDC, about 20.1 million adults aged 20 and older had coronary heart disease (CAD) in the United States in 2020. It also stated that coronary heart disease is the most common type of heart disease in the United States. The high prevalence of cardiac diseases among the population reaped the demand for stents.

The advancements in technology, increasing product approvals, and partnerships and acquisitions by key players are driving the growth of the segment. For instance, in January 2022, Cook Medical received a breakthrough device designation from the US FDA on a new drug-eluting stent for below the knee (BTK). This novel stent is used to treat individuals with limb-threatening persistent ischemia. In August 2021, Sinomed launched its HT Supreme drug-eluting stent in Ireland. Such launches are projected to augment the growth of the segment during the forecast period.

North America is Expected to Dominate the Stents Market During the Forecast Period

North America is expected to dominate the market owing to factors such as the rising incidence of chronic diseases, the growing geriatric population, the strong presence of industry players in the region, better healthcare infrastructure, and increased awareness among people and healthcare industry stakeholders about available technologies in the region.

In addition, the rise in the geriatric population and the increase in the incidence of lifestyle diseases are actively affecting the growth of the market studied. For instance, according to the Statistics Canada 2021 census, there were around 7,021,430 people aged 65 years or above in 2021, out of which 3,224,680 were males, and 3,796,750 were females. The geriatric population is prone to critical cardiovascular diseases that require stents for treatment. Thus, the surge in the geriatric population in the region is likely to augment the growth of the market.

The engagement of key market players and institutions in research and development in the region for innovation in the stents used for different conditions is projected to augment the growth of the market. For instance, in October 2021, Boston Scientific Corporation presented positive clinical trial results for the Eluvia drug-eluting vascular stent system during a clinical trial presentation at the Vascular InterVentional Advances (VIVA) meeting in Las Vegas. According to the data from the EMINENT trial, the Eluvia stent outperformed self-expanding bare metal stents (BMS) for the treatment of patients with peripheral arterial disease (PAD) and superficial femoral artery (SFA) lesions up to 210 mm in length. The study included 775 patients, making it one of the biggest drug-eluting stent randomized trials for peripheral artery disease treatment to date. Such clinical trials are anticipated to fuel the use of stents in the region.

Therefore, owing to the abovementioned factors, the market studied is anticipated to grow in the North American region.

Stents Market Competitor Analysis

The stents market is fragmented in nature due to the presence of companies operating globally and regionally. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well known. Some key market players are Boston Scientific Corporation, Abbott, Medtronic, B. Braun, Becton, Dickinson and Company, Microport Scientific Corporation, Biotronik, Cook Group, Allium Medical Solutions Ltd, Elixir Medical, and Terumo Corporation, among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Chronic Diseases
    • 4.2.2 Increasing Geriatric Population
    • 4.2.3 Technological Advancements in Stent Development
  • 4.3 Market Restraints
    • 4.3.1 Stringent Approval Process for Stents
    • 4.3.2 High Product Recalls
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Product
    • 5.1.1 Coronary Stents
      • 5.1.1.1 Drug-eluting Stents
      • 5.1.1.2 Bare-metal coronary Stents
      • 5.1.1.3 Bioabsorbable Stents
    • 5.1.2 Peripheral stents
      • 5.1.2.1 Iliac Stents
      • 5.1.2.2 Femoral-popliteal Stents
      • 5.1.2.3 Renal and Related Stents
      • 5.1.2.4 Carotid Stents
    • 5.1.3 Stent Implants
  • 5.2 By Material
    • 5.2.1 Metallic biomaterials
    • 5.2.2 Polymeric biomaterials
    • 5.2.3 Natural biomaterials
  • 5.3 By Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Boston Scientific Corporation
    • 6.1.2 Abbott
    • 6.1.3 Medtronic
    • 6.1.4 B. Braun SE
    • 6.1.5 Becton, Dickinson and Company
    • 6.1.6 Microport Scientific Corporation
    • 6.1.7 Biotronik
    • 6.1.8 Cook Group
    • 6.1.9 Allium Medical Solutions Ltd
    • 6.1.10 Elixir Medical
    • 6.1.11 Terumo Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS